Cited by 321Protein Kinase Regulation and GTPase SignalingMelanoma and MAPK PathwaysProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

KRAS as a Therapeutic Target

Open access

McCormick, Frank·2015·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-14-2662PMC PMC4407814

Open this paper in CoChat — free account

Abstract

KRAS proteins play a major role in human cancer, but have not yielded to therapeutic attack. New technologies in drug discovery and insights into signaling pathways that KRAS controls have promoted renewed efforts to develop therapies through direct targeting of KRAS itself, new ways of blocking KRAS processing, or by identifying targets that KRAS cancers depend on for survival. Although drugs that block the well-established downstream pathways, RAF–MAPK and PI3K, are being tested in the clinic, new efforts are under way to exploit previously unrecognized vulnerabilities, such as altered metabolic networks, or novel pathways identified through synthetic lethal screens. Furthermore, new ways of suppressing KRAS gene expression and of harnessing the immune system offer further hope that new ways of treating KRAS are finally coming into view. These issues are discussed in this edition of CCR Focus. Clin Cancer Res; 21(8); 1797–801. ©2015 AACR. See all articles in this CCR Focus section, “Targeting RAS-Driven Cancers.”

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-2662

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · cited 1×
“In pancreatic cancer, KRAS mutations are detected in the earliest lesions and are retained in all metastases (17).”
Background
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M. T., Deuker, M. M., McCormick, F. P., & McMahon, M. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3760 · Cited by 850
Self-citation
A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
Dragging ras back in the ring
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795
Self-citation
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744

Show all 41 references

Sorted by citations

Drugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M. M., & Garrido‐Laguna, I. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 403
The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Metabolic Codependencies in the Tumor Microenvironment
Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 349
Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers
Mukhopadhyay, S., Goswami, D., Adiseshaiah, P. P., Burgan, W., Yi, M., Guerin, T. M., Kozlov, S. V., Nissley, D. V., & McCormick, F. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1363 · Cited by 279
Self-citation
Capsule Networks – A survey
Mensah, P. K., Adekoya, A. F., Ayidzoe, M. A., & Baagyere, E. Y. (2019) · Journal of King Saud University - Computer and Information Sciences · doi:10.1016/j.jksuci.2019.09.014 · Cited by 303
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 241
A biologically stable DNAzyme that efficiently silences gene expression in cells
Wang, Y., Nguyen, K., Spitale, R. C., & Chaput, J. C. (2021) · Nature Chemistry · doi:10.1038/s41557-021-00645-x · Cited by 233
Metabolic Dependencies in RAS -Driven Cancers
Kimmelman, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2425 · Cited by 230
Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway
Jeong, W.-J., Ro, E. J., & Choi, K.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0049-y · Cited by 220
Pancreatic Cancer Metabolism: Breaking It Down to Build It Back Up
Perera, R. M., & Bardeesy, N. M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0671 · Cited by 218
Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy
Yossef, R., Tran, E., Deniger, D. C., Gros, A., Pasetto, A., Parkhurst, M. R., Gartner, J. J., Prickett, T. D., Cafri, G., Robbins, P. F., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122467 · Cited by 213
Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis
Huang, J., Jiang, G., Song, Q., Gu, X. Q., Meng, H., Wang, X.-L., Song, H., Chen, L., Lin, Y., Jiang, D. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15144 · Cited by 212
Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules
Grabocka, E., & Bar‐Sagi, D. (2016) · Cell · doi:10.1016/j.cell.2016.11.035 · Cited by 208
Adenomyosis pathogenesis: insights from next-generation sequencing
Bulun, S. E., Yıldız, Ş., Adli, M., & Wei, J. (2021) · Human Reproduction Update · doi:10.1093/humupd/dmab017 · Cited by 216
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
Platinum coordination compounds with potent anticancer activity
Deo, K. M., Ang, D. L., McGhie, B. S., Rajamanickam, A., Dhiman, A., Khoury, A., Holland, J. M., Bjelosevic, A., Pages, B. J., Gordon, C., et al. (2017) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2017.11.014 · Cited by 193
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
Kwan, A. K., Piazza, G. A., Keeton, A. B., & Leite, C. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02225-w · Cited by 200
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Porru, M., Pompili, L., Caruso, C., Biroccio, A., & Leonetti, C. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0719-1 · Cited by 181
An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses
Meraz, I. M., Majidi, M., Meng, F., Shao, R., Ha, M. J., Neri, S., Fang, B., Lin, S. H., Tinkey, P. T., Shpall, E. J., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0874 · Cited by 165
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129
Combined Mutation of Apc, Kras , and Tgfbr2 Effectively Drives Metastasis of Intestinal Cancer
Sakai, E., Nakayama, M., Oshima, H., Kouyama, Y., Niida, A., Fujii, S., Ochiai, A., Nakayama, K. I., Mimori, K., Suzuki, Y., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3303 · Cited by 133
Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination
Ham, J., Costa, C., Sano, R., Lochmann, T. L., Sennott, E. M., Patel, N. U., Dastur, A., Gomez‐Caraballo, M., Krytska, K., Hata, A. N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.002 · Cited by 135
Nonhistone Lysine Methylation in the Regulation of Cancer PathwaysPreprint
Carlson, S. M., & Gozani, O. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026435 · Cited by 133
A Quadruple‐Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines
Petruzzella, E., Braude, J. P., Aldrich-Wright, J. R., Gandin, V., & Gibson, D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201706739 · Cited by 121
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 119
Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Knudsen, E. S., O'Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 115
Improving prospects for targeting RAS
Singh, H., Longo, D. L., & Chabner, B. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1052 · Cited by 107
Recent Advances in Covalent Drug Discovery
Schaefer, D., & Cheng, X. (2023) · Pharmaceuticals · doi:10.3390/ph16050663 · Cited by 117
Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance
Dietrich, P., Koch, A., FRITZ, V. K., Hartmann, A., Bosserhoff, A., & Hellerbrand, C. (2017) · Gut · doi:10.1136/gutjnl-2017-315402 · Cited by 99
Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC
Yang, F., Wen, Y., Wang, C., Zhou, Y., Zhou, Y., Zhang, Z.-M., Liu, T., & Lu, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114088 · Cited by 109
Otubain 1: a non-canonical deubiquitinase with an emerging role in cancer
Saldana, M., VanderVorst, K., Berg, A. L., Lee, H., & Carraway, K. L. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0264 · Cited by 98
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities
Qin, Q., Yu, R., Eriksson, J., Tsai, H., & Zhu, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216859 · Cited by 102
Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1
Wang-Bishop, L., Chen, Z., Gomaa, A. R., Lockhart, A. C., Salaria, S. N., Wang, J., Lewis, K. B., Ecsedy, J., Washington, K. M., Beauchamp, R. D., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.10.030 · Cited by 92
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
Zhu, X., Cao, Y., Liu, W., Ju, X., Zhao, X., Jiang, L., Ye, Y., Jin, G., & Zhang, H. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00066-3 · Cited by 93
Molecular electronics sensors on a scalable semiconductor chip: A platform for single-molecule measurement of binding kinetics and enzyme activity
Fuller, C. W., Padayatti, P. S., Abderrahim, H., Adamiak, L., Alagar, N., Ananthapadmanabhan, N., Baek, J., Chinni, S., Choi, C., Delaney, K. J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2112812119 · Cited by 95
Orthogonal ring-closing alkyne and olefin metathesis for the synthesis of small GTPase-targeting bicyclic peptides
Cromm, P. M., Schaubach, S., Spiegel, J., Fürstner, A., Grossmann, T. N., & Waldmann, H. (2016) · Nature Communications · doi:10.1038/ncomms11300 · Cited by 93
Kirsten Ras* oncogene: Significance of its discovery in human cancer research
Tsuchida, N., Murugan, A. K., & Grieco, M. (2016) · Oncotarget · doi:10.18632/oncotarget.8773 · Cited by 94
KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK–ERK pathway in pancreatic cancer
Yang, K., Li, Y., Lian, G., Lin, H., Shang, C., Zeng, L., Chen, S., Li, J., Huang, C., Huang, K., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31248 · Cited by 88
Androgen receptor‐regulated circFNTA activates KRAS signaling to promote bladder cancer invasion
Chen, J., Sun, Y., Ou, Z., Yeh, S., Huang, C., You, B., Tsai, Y., Sheu, T., Zu, X., & Chang, C. (2020) · EMBO Reports · doi:10.15252/embr.201948467 · Cited by 86
The Ras switch in structural and historical perspective
Gasper, R., & Wittinghofer, F. (2019) · Biological Chemistry · doi:10.1515/hsz-2019-0330 · Cited by 92
Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality
Kitagawa, M., Liao, P.-J., Lee, K. H., Wong, J., Shang, S. C., Minami, N., Sampetrean, O., Saya, H., Dai, L., Prabhu, N., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02287-5 · Cited by 84
Self-citation
Two Distinct Structures of Membrane‐Associated Homodimers of GTP‐ and GDP‐Bound KRAS4B Revealed by Paramagnetic Relaxation Enhancement
Lee, K., Fang, Z., Enomoto, M., Gasmi-Seabrook, G. M. C., Zheng, L., Koide, S., Ikura, M., & Marshall, C. B. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202001758 · Cited by 78
Direct Modulation of Small GTPase Activity and Function
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504357 · Cited by 80
Drugging K-RasG12C through covalent inhibitors: Mission possible?
Ni, D., Li, X., He, X., Zhang, H., Zhang, J., & Lu, S. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.007 · Cited by 73
Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Marcus, K., & Mattos, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2148 · Cited by 75
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
O’Sullivan, É., Keogh, A., Henderson, B., Finn, S. P., Gray, S. G., & Gately, K. A. (2023) · Cancers · doi:10.3390/cancers15061635 · Cited by 84
Current Approaches in NSCLC Targeting K-RAS and EGFR
Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74
The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions
Nakhaeizadeh, H., Amin, E., Nakhaei‐Rad, S., Dvorský, R., & Ahmadian, M. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167145 · Cited by 71
The natural compound gracillin exerts potent antitumor activity by targeting mitochondrial complex II
Min, H., Jang, H.-J., Park, K. H., Hyun, S. Y., Park, S. J., Kim, J. H., Son, J., Kang, S. S., & Lee, H. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2041-z · Cited by 75
RETRACTION: Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial
Zhu, X., Cao, Y., Liu, W., Ju, X., Zhao, X., Jiang, L., Ye, Y., Jin, G., & Zhang, H. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00286-2 · Cited by 71
Retracted
Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer
Theard, P. L., Sheffels, E., Sealover, N. E., Linke, A. J., Pratico, D. J., & Kortum, R. L. (2020) · eLife · doi:10.7554/elife.58204 · Cited by 69
Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology
Huang, J., & Xiao, K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081586 · Cited by 73
Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression
Gao, Q., Ouyang, W., Kang, B., Han, X., Xiong, Y., Ding, R., Li, Y., Wang, F., Huang, L., Chen, L., et al. (2020) · Theranostics · doi:10.7150/thno.42325 · Cited by 72
Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Hasbullah, H. H., & Musa, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111941 · Cited by 73
Small molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulatesKRASexpression in pancreatic ductal adenocarcinoma cells
Pramanik, S., Chen, Y., Song, H., Khutsishvili, I., Marky, L. A., Ray, S., Natarajan, A., Singh, P. K., & Bhakat, K. K. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac172 · Cited by 60
KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs
Liu, H., Sun, M., Liu, Z., Kong, C., Kong, W., Ye, J., Gong, J., Huang, D. C. S., & Qian, F. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.014 · Cited by 67
Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation
Sheffels, E., Sealover, N. E., Wang, C., Kim, D., Vazirani, I. A., Lee, E., Terrell, E. M., Morrison, D. K., Luo, J., & Kortum, R. L. (2018) · Science Signaling · doi:10.1126/scisignal.aar8371 · Cited by 56
Photodynamic Therapy for ras -Driven Cancers: Targeting G-Quadruplex RNA Structures with Bifunctional Alkyl-Modified Porphyrins
Ferino, A., Nicoletto, G., D’Este, F., Zorzet, S., Lago, S., Richter, S. N., Tikhomirov, A. S., Shchekotikhin, A. E., & Xodo, L. E. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01577 · Cited by 60
Leaving the Lysosome Behind: Novel Developments in Autophagy Inhibition
Solitro, A. R., & MacKeigan, J. P. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.166 · Cited by 59
YAP and AP-1 Cooperate to Initiate Pancreatic Cancer Development from Ductal Cells in Mice
Park, J., Eisenbarth, D., Choi, W., Kim, H., Choi, C., Lee, D., & Lim, D. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0907 · Cited by 59
USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer
Fraile, J. M., Manchado, E., Lujambio, A., Quesada, V., Campos-Iglesias, D., Webb, T. R., Lowe, S. W., López-Otı́n, C., & Freije, J. M. P. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762757 · Cited by 54
Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition
Dietrich, P., Kuphal, S., Spruß, T., Hellerbrand, C., & Bosserhoff, A. (2017) · Oncogene · doi:10.1038/onc.2017.391 · Cited by 54
Bis(acetylacetonato)-oxidovanadium(IV) and sodium metavanadate inhibit cell proliferation via ROS-induced sustained MAPK/ERK activation but with elevated AKT activity in human pancreatic cancer AsPC-1 cells
Wu, J.-X., Hong, Y.-H., & Yang, X.-G. (2016) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-016-1389-0 · Cited by 49
Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-β) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis
Vivekanandhan, S., & Mukhopadhyay, D. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.014 · Cited by 53
Chemical evolution of an autonomous DNAzyme with allele-specific gene silencing activity
Nguyen, K., Malik, T. N., & Chaput, J. C. (2023) · Nature Communications · doi:10.1038/s41467-023-38100-9 · Cited by 52
Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy
Zhao, X., & Subramanian, S. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.004 · Cited by 51
An overview of recent molecular dynamics applications as medicinal chemistry tools for the undruggable site challenge
Perricone, U., Gulotta, M. R., Lombino, J., Parrino, B., Cascioferro, S., Diana, P., Cirrincione, G., & Padova, A. (2018) · MedChemComm · doi:10.1039/c8md00166a · Cited by 54
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma
Dietrich, P., Gaza, A., Wormser, L., FRITZ, V. K., Hellerbrand, C., & Bosserhoff, A. (2019) · Neoplasia · doi:10.1016/j.neo.2018.11.011 · Cited by 49
Selective targeting of point-mutated KRAS through artificial microRNAs
Acunzo, M., Romano, G., Nigita, G., Veneziano, D., Fattore, L., Laganà, A., Zanesi, N., Fadda, P., Fassan, M., Rizzotto, L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620562114 · Cited by 48
PDAC-ANN: an artificial neural network to predict pancreatic ductal adenocarcinoma based on gene expression
Almeida, P. P., Cardoso, C. P., & de Freitas, L. M. (2020) · BMC Cancer · doi:10.1186/s12885-020-6533-0 · Cited by 48
HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation
Chia, L., Wang, B., Kim, J., Luo, L., Shuai, S., Herrera, I., Chen, S. Y., Li, L., Xian, L., Huso, T. H., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci151601 · Cited by 52
Studying protein–protein interactions: progress, pitfalls and solutions
Hayes, S. L., Malacrida, B., Bailey‐Whyte, M., & Kiely, P. A. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160092 · Cited by 47
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards
Danesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 52
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Indini, A., Rijavec, E., Ghidini, M., Cortellini, A., & Grossi, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050653 · Cited by 49
Mutated RAS: Targeting the “Untargetable” with T Cells
Chatani, P. D., & Yang, J. C. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2138 · Cited by 45
Exploiting macropinocytosis for drug delivery into KRAS mutant cancer
Liu, H., & Qian, F. (2022) · Theranostics · doi:10.7150/thno.67889 · Cited by 46
Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis
Mou, H., Moore, J., Malonia, S. K., Li, Y., Ozata, D. M., Hough, S., Song, C.-Q., Smith, J. L., Fischer, A., Weng, Z., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620861114 · Cited by 46
Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct
Yang, C., Huang, W., Tsai, J., Cheng, A., Chen, C.-C., Hsu, H., & Jeng, Y. (2019) · Modern Pathology · doi:10.1038/s41379-019-0306-9 · Cited by 46
The Methods Employed in Mass Spectrometric Analysis of Posttranslational Modifications (PTMs) and Protein–Protein Interactions (PPIs)
Yakubu, R., Nieves, E., & Weiss, L. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-15950-4_10 · Cited by 46
An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development
Shankar, S., Tien, J. C.-Y., Siebenaler, R. F., Chugh, S., Dommeti, V. L., Zelenka-Wang, S., Waninger, J. J., Juckette, K. M., Xu, A., Wang, X.-M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16309-2 · Cited by 47
Targeting the RAS upstream and downstream signaling pathway for cancer treatment
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176727 · Cited by 51
Quantitative structure–activity relationships analysis, homology modeling, docking and molecular dynamics studies of triterpenoid saponins as Kirsten rat sarcoma inhibitors
Stitou, M., Toufik, H., Bouachrıne, M., & Lamchouri, F. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1707122 · Cited by 44
The role of KRAS splice variants in cancer biology
Nuevo‐Tapioles, C., & Philips, M. R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1033348 · Cited by 48
Structural fingerprints, interactions, and signaling networks of RAS family proteins beyond RAS isoforms
Nakhaei‐Rad, S., Haghighi, F., Nouri, P., Adariani, S. R., Lissy, J., Jasemi, N. S. K., Dvorský, R., & Ahmadian, M. R. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1431605 · Cited by 44
Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord–Stromal Tumors: A Contemporary Review
Maoz, A., Matsuo, K., Ciccone, M. A., Matsuzaki, S., Klar, M., Roman, L. D., Sood, A. K., & Gershenson, D. M. (2020) · Cancers · doi:10.3390/cancers12061398 · Cited by 43
Dual Inhibitions on Glucose/Glutamine Metabolisms for Nontoxic Pancreatic Cancer Therapy
Xu, Y., Yu, Z., Fu, H., Guo, Y., Hu, P., & Shi, J. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c00111 · Cited by 43
The role of wild-type RAS in oncogenic RAS transformation
Sheffels, E., & Kortum, R. L. (2021) · Genes · doi:10.3390/genes12050662 · Cited by 42
Selective binding of a bioactive porphyrin-based photosensitizer to the G-quadruplex from the KRAS oncogene promoter
Caterino, M., D’Aria, F., Kustov, A. V., Belykh, D. V., Khudyaeva, I. S., Starseva, O. M., Березин, Д. Б., Игоревна, П. Я., Усачева, Т. Р., Amato, J., et al. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.12.152 · Cited by 42
Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C
Cannataro, V. L., Gaffney, S. G., Stender, C., Zhao, Z.-M., Philips, M. R., Greenstein, A. E., & Townsend, J. P. (2018) · Oncogene · doi:10.1038/s41388-017-0105-z · Cited by 43
Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer
Koujima, T., Tazawa, H., Ieda, T., Araki, H., Fushimi, T., Shoji, R., Kuroda, S., Kikuchi, S., Yoshida, R., Umeda, Y., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.016 · Cited by 48
The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer
Fujii, A., Masuda, T., Iwata, M., Tobo, T., Wakiyama, H., Koike, K., Kosai, K., Nakano, T., Kuramitsu, S., Kitagawa, A., et al. (2021) · Cancer Science · doi:10.1111/cas.14858 · Cited by 41
New structural and functional insight into the regulation of Ras
Kano, Y., Cook, J. D., Lee, J. E., & Ohh, M. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.006 · Cited by 38
Identification of cervical cancer stem cells using single-cell transcriptomes of normal cervix, cervical premalignant lesions, and cervical cancer
Zhang, T., Zhuang, L., Muaibati, M., Wang, D., Abasi, A., Tong, Q., Ma, D., Jin, L., & Huang, X. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104612 · Cited by 45
An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth
Vidimar, V., Beilhartz, G. L., Park, M., Biancucci, M., Kieffer, M. B., Gius, D. R., Melnyk, R. A., & Satchell, K. J. F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2000312117 · Cited by 39

Authors: McCormick, F.
Affiliations: Frederick National Laboratory for Cancer Research (US)
Corresponding author: McCormick, Frank
ORCID: McCormick, Frank
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2015-04-14
Volume: 21
Issue: 8
Pages: 1797-1801
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-14-2662
PMC: PMC4407814
OpenAlex: W2062410054
Cited by: 320
References: 41
Citations by year: 2026: 10 · 2025: 22 · 2024: 18 · 2023: 35 · 2022: 26 · 2021: 32 · 2020: 45 · 2019: 35 · 2018: 31 · 2017: 29 · 2016: 26 · 2015: 10
FWCI: 3.10
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Cancer Institute (U01CA168370)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: KRAS, KRAS-targeted therapy, MAPK/ERK pathway, PI3K signaling, synthetic lethality, cancer metabolism, cancer immunotherapy, KRAS oncogenic signaling, drug discovery
MeSH terms: Animals, Antineoplastic Agents, Cell Transformation, Neoplastic, Humans, Immunity, Immunotherapy, Mutation, Neoplasms, Genetic Therapy, Signal Transduction, Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Protein Subunits, RNA Interference, RNA, Small Interfering, Protein Kinase Inhibitors, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

KRAS as a Therapeutic Target

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks